ArticleDrug and alcohol dependence2019
Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.
Article in Drug and alcohol dependence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of Cannabis Use Disorder: A Meta-Analysis of Population Surveys.Journal of studies on alcohol and drugs · 2025Pooled it
- Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.Frontiers in psychiatry · 2023Pooled it
- Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.Addiction (Abingdon, England) · 2024Trial
- A remote brief intervention plus social media messaging for cannabis use among emerging adults: A pilot randomized controlled trial in emergency department patients.Addictive behaviors · 2023Trial
- Emerging adult perceptions of higher-risk cannabis consumption behaviours.Harm reduction journal · 2023Trial
- The role of subcortical brain tissue iron as an indicator of dopamine neurophysiology in adolescent cannabis use.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Modes of cannabis administration, cannabis and tobacco co-use, and associations with respiratory and cannabis use outcomes in a permissive medical cannabis state.Addictive behaviors · 2026Article
- Influence of cannabis potency on mental health outcomes among adolescents and young adults: scoping review.BJPsych open · 2026Review
- Cannabis use and beliefs among people in recovery from substance use disorders.Journal of cannabis research · 2026Article
- Prenatal and Postnatal Exposure to Tobacco and Cannabis and Child Aggression at Early School Age: Role of Early Maternal Sensitivity.Child psychiatry and human development · 2026Article
- The effectiveness of psychological interventions delivered by health professionals for adult cannabis use in community settings: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Review
- Adult-use cannabis legalization in the united states: a scoping review of outcome monitoring recommendations.BMC public health · 2025Article
- Differences in Cannabis and Cannabidiol Attitudes, Perceptions, and Behaviors Between US Adolescents Receiving Mood Disorder Treatment and Their Parents Across Legal Contexts.International journal of environmental research and public health · 2025Article
- Associations between recreational cannabis legalization and cannabis use disorder treatment outcomes in California, 2010-2021.Journal of cannabis research · 2025Article
- Exploring cannabis consumption stigma in Canada with consideration of age and gender differences.Addictive behaviors reports · 2025Article
- Cannabis Use Among Older Adults.JAMA network open · 2025Article
- Commentary on Borodovsky et al.: Enhancing research on THC quantification-Consumer awareness through accurate labelling.Addiction (Abingdon, England) · 2025Article
- Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.European archives of psychiatry and clinical neuroscience · 2025Review
- Cannabis use characteristics and associations with problematic use outcomes, quitting-related factors, and mental health among US young adults.Substance abuse treatment, prevention, and policy · 2025Article
- Cannabis Products and Use Patterns Associated with Cannabis Use Disorder Symptoms Among Youth in Southern California.Cannabis (Albuquerque, N.M.) · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo determine if higher potency cannabis is associated with earlier progression to regular cannabis use, daily cannabis use, and cannabis use disorder symptom onset.
methodsData sources were the Michigan Longitudinal Study, an ongoing prospective, high-risk family study investigating the course and predictors for substance use disorders among youth beginning prior to school entry and time-parallel national average trends in delta-9-tetrahydrocannabinol (i.e., psychoactive compound in cannabis). The national average trends in delta-9-tetrahydrocannabinol were used to estimate potency level for the individual. Only cannabis users were included in analyses (n = 527).
resultsCox regression showed an increased risk of progression from cannabis initiation to cannabis use disorder symptom onset by 1.41 times (p < .001) for each unit increase in national average delta-9-tetrahydrocannabinol as compared to those not endorsing CUD symptom onset, adjusting for sex, regular use, and cohort effects. Accounting for regular use, individuals initiating cannabis at national average 4.9% delta-9-tetrahydrocannabinol were at 1.88 times (p = .012) higher risk for cannabis use disorder symptom onset within one year compared to those who did not endorse CUD symptom onset, while those initiating cannabis at national average 12.3% delta-9-tetrahydrocannabinol were at 4.85 times (p = .012) higher risk within one year.
conclusionsThis study provides prospective evidence suggesting higher potency cannabis, on average in the U.S., increases risk for onset of first cannabis use disorder symptom. Development of guidelines regarding cannabis potency is critical for reducing the costs associated with negative health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.